CYP19A1 and breast cancer: Previous reports have suggested that Hsp90 inhibition may overcome endocrine resistance in tamoxifen- and aromatase-resistant breast cancer cell lines [23, 47] and preliminary studies have shown that ganetespib exhibits such activity (D. Proia and L. Whitesell, unpublished data).